Cargando…
Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia
The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097876/ https://www.ncbi.nlm.nih.gov/pubmed/30107177 http://dx.doi.org/10.1016/j.ccell.2018.07.007 |
_version_ | 1783348376893390848 |
---|---|
author | Vanden Bempt, Marlies Demeyer, Sofie Broux, Michaël De Bie, Jolien Bornschein, Simon Mentens, Nicole Vandepoel, Roel Geerdens, Ellen Radaelli, Enrico Bornhauser, Beat C. Kulozik, Andreas E. Meijerink, Jules P. Bourquin, Jean-Pierre de Bock, Charles E. Cools, Jan |
author_facet | Vanden Bempt, Marlies Demeyer, Sofie Broux, Michaël De Bie, Jolien Bornschein, Simon Mentens, Nicole Vandepoel, Roel Geerdens, Ellen Radaelli, Enrico Bornhauser, Beat C. Kulozik, Andreas E. Meijerink, Jules P. Bourquin, Jean-Pierre de Bock, Charles E. Cools, Jan |
author_sort | Vanden Bempt, Marlies |
collection | PubMed |
description | The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a transgenic mouse model and human T-ALL cells. Using integrated ChIP-sequencing, ATAC-sequencing, and RNA-sequencing data, we demonstrate that TLX1 and STAT5, the downstream effector of NUP214-ABL1, co-bind poised enhancer regions, and cooperatively activate the expression of key proto-oncogenes such as MYC and BCL2. Inhibition of STAT5, downregulation of TLX1 or MYC, or interference with enhancer function through BET-inhibitor treatment leads to reduction of target gene expression and induction of leukemia cell death. |
format | Online Article Text |
id | pubmed-6097876 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cell Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60978762018-08-20 Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia Vanden Bempt, Marlies Demeyer, Sofie Broux, Michaël De Bie, Jolien Bornschein, Simon Mentens, Nicole Vandepoel, Roel Geerdens, Ellen Radaelli, Enrico Bornhauser, Beat C. Kulozik, Andreas E. Meijerink, Jules P. Bourquin, Jean-Pierre de Bock, Charles E. Cools, Jan Cancer Cell Article The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a transgenic mouse model and human T-ALL cells. Using integrated ChIP-sequencing, ATAC-sequencing, and RNA-sequencing data, we demonstrate that TLX1 and STAT5, the downstream effector of NUP214-ABL1, co-bind poised enhancer regions, and cooperatively activate the expression of key proto-oncogenes such as MYC and BCL2. Inhibition of STAT5, downregulation of TLX1 or MYC, or interference with enhancer function through BET-inhibitor treatment leads to reduction of target gene expression and induction of leukemia cell death. Cell Press 2018-08-13 /pmc/articles/PMC6097876/ /pubmed/30107177 http://dx.doi.org/10.1016/j.ccell.2018.07.007 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Vanden Bempt, Marlies Demeyer, Sofie Broux, Michaël De Bie, Jolien Bornschein, Simon Mentens, Nicole Vandepoel, Roel Geerdens, Ellen Radaelli, Enrico Bornhauser, Beat C. Kulozik, Andreas E. Meijerink, Jules P. Bourquin, Jean-Pierre de Bock, Charles E. Cools, Jan Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia |
title | Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia |
title_full | Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia |
title_fullStr | Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia |
title_full_unstemmed | Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia |
title_short | Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia |
title_sort | cooperative enhancer activation by tlx1 and stat5 drives development of nup214-abl1/tlx1-positive t cell acute lymphoblastic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097876/ https://www.ncbi.nlm.nih.gov/pubmed/30107177 http://dx.doi.org/10.1016/j.ccell.2018.07.007 |
work_keys_str_mv | AT vandenbemptmarlies cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT demeyersofie cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT brouxmichael cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT debiejolien cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT bornscheinsimon cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT mentensnicole cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT vandepoelroel cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT geerdensellen cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT radaellienrico cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT bornhauserbeatc cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT kulozikandrease cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT meijerinkjulesp cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT bourquinjeanpierre cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT debockcharlese cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia AT coolsjan cooperativeenhanceractivationbytlx1andstat5drivesdevelopmentofnup214abl1tlx1positivetcellacutelymphoblasticleukemia |